Xconomy Boston

Mersana Raises $4M in Note Placement

Rebecca Zacks10/24/08

Mersana Therapeutics has completed a convertible note placement worth $4 million, officials of the Cambridge, MA-based cancer drug developer told Mass High Tech. The new funding brings Mersana’s total private investment raised to date to about $36 million, according to Mass High Tech; Fidelity Biosciences, Harris & Harris Group, PureTech Ventures, ProQuest Investments, and Rho Ventures are all backers of the firm. Mersana’s lead drug candidate began early stage clinical trials in 2007.

Add Your Thoughts

You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted.
By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.